[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 21, Issue 2 (6-2013) ::
Journal of Ilam University of Medical Sciences 2013, 21(2): 28-36 Back to browse issues page
Comparison of metformin and pioglitazone on hs-CRP levels in patients with Type II diabetes
Amir Ziaee1 , Sima Hashemipour1 , Samiramis Ghavam2 , Amir Javadi1 , Ramak Ghavam * 3, Ameneh Barikani1 , Neda Esmailzadehha1
1- Metabolic Disease Research Center, Qazvin University of Medical Science, Qazvin, Iran
2- Ilam University of Medical Sciences
3- Metabolic Disease Research Center, Qazvin University of Medical Science, Qazvin, Iran , ramak.ghavam@yahoo.com
Abstract:   (28537 Views)
Background: Heart disease, particularly coronary heart disease is a major cause of mortality among patients with diabetes mellitus. High level of hs-CRP is considered as a risk factor for heart diseases. Treatment with pioglitazone in patients with or without type II diabetes decreases serum concentrations of hs-CRP. The purpose of this study was to compare the effects of pioglitazone and metformin on hs-CRP level. Material and methods: A randomized clinical trial was performed on 40 patients with type 2 diabetes and defined inclusion criteria. Patients were divided into two groups receiving metformin and pioglitazone. Blood levels of cholesterol, triglycerides, fasting blood glucose, Alanine transaminase, Aspartat aminotransferase, HbA1C and hs-CRP were measured in all subjects before and after 3 month drug therapy. The average change in each group before and after drug therapy were analyzed by paired T-test, the mean change between groups were compared by T-test. Results: In both groups, hs-CRP level was significantly decreased after drug therapy. The mean change of hs-CRP, HbA1C, cholesterol was significantly higher in metformin treated group. Conclusion: Since the average reduction in the level of hs-CRP, cholesterol and HbA1C in diabetic patients treated with metformin is significantly higher than patients treated with pioglitazone treatment with metformin is recommended to reduce risk of heart disease
Keywords: Diabetes mellitus, Metformin, Pioglitazone, hs-CRP, HbA1C
Full-Text [PDF 217 kb]   (6936 Downloads)    
Type of Study: Research | Subject: gp
Received: 2012/04/18 | Accepted: 2013/08/6 | Published: 2013/09/1
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ziaee A, Hashemipour S, Ghavam S, Javadi A, Ghavam R, Barikani A et al . Comparison of metformin and pioglitazone on hs-CRP levels in patients with Type II diabetes. J. Ilam Uni. Med. Sci. 2013; 21 (2) :28-36
URL: http://sjimu.medilam.ac.ir/article-1-596-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 2 (6-2013) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.13 seconds with 41 queries by YEKTAWEB 4653